РАМОН И КАХАЛЬ АГУЭРАС Сантьяго (ES),ЭРНАНДЕС ЛОСА Хавьер (ES),ХИМЕНО ДОНЬЯКЕ Хосе Мария (ES),РАЙМОН Эрик (FR)
申请号：
RU2010140890/15
公开号：
RU2010140890A
申请日:
2009.03.06
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A method of treating cancer, comprising administering to a patient in need of such treatment a therapeutically effective amount of PM02734, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of another anti-cancer agent selected from cisplatin, gemcitabine, paclitaxel, oxaliplatin, 5-fluorouracil, trabecidine, rapamycin and sunitinib, or a pharmaceutically acceptable salt thereof. ! 2. A method of increasing the therapeutic efficacy of an anticancer agent selected from cisplatin, gemcitabine, paclitaxel, oxaliplatin, 5-fluorouracil, trabectedin, rapamycin and sunitinib in the treatment of cancer, comprising administering to the patient in need of said anticancer agent and a therapeutically effective amount of PM02734, or its a pharmaceutically acceptable salt. ! 3. The method according to claim 1, wherein the cancer to be treated is selected from testicular cancer, bladder cancer, lung cancer, esophageal cancer, stomach cancer, ovarian cancer, breast cancer, pancreatic cancer, colon cancer, leukemia, melanoma and cancer prostate gland. ! 4. The method according to claim 2, wherein the cancer to be treated is selected from cancer of the testis, bladder cancer, lung cancer, cancer of the esophagus, stomach cancer, ovarian cancer, breast cancer, pancreatic cancer, colon cancer, leukemia, melanoma and cancer prostate gland. ! 5. The method according to any one of claims 1 to 4, in which PM02734, or a pharmaceutically acceptable salt thereof, and another anticancer agent selected from cisplatin, gemcitabine, paclitaxel, oxaliplatin, 5-fluorouracil, trabecidine, rapamycin and sunitinib, or its pharmaceutically acceptable salt, make up part one1. Способ лечения рака, включающий введение пациенту, нуждающемуся в таком лечении, терапевтически эффективного количества РМ02734, или его фармацевтически приемлемой соли, и терапевтически эффективного количества другого противоракового средства, выбранного из цисплатина, гемцитабина, паклитаксе
